

RP02851

Leader in Biomolecular Solutions for Life Science



# Recombinant Mouse CXCL9/MIG Protein

Catalog No.: RP02851

Recombinant

## Sequence Information

### Species Gene ID Swiss Prot

<I>Pichia</I> 117329 P18340

>

### Tags

C-His

### Synonyms

Mig; Scyb9

## Product Information

### Source

<I>Pichia</I>

### Purification

≥ 95 % as determined by SDS-PAGE.

### Endotoxin

Please contact us for more information.

### Formulation

Lyophilized from sterile PBS, pH 7.4

### Reconstitution

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stabilizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

## Contact



[www.abclonal.com](http://www.abclonal.com)

## Background

Chemokine (C-X-C motif) ligand 9 (CXCL9), also known as Monokine induced by gamma interferon (MIG), is a small cytokine belonging to the CXC chemokine family. The function of this chemokine has not been specifically defined; however, it is thought to be involved in T cell trafficking. CXCL9/MIG functions as one of the three ligands of chemokine receptor CXCR3 which is a G protein-coupled receptor found predominantly on T cells. CXCL9/MIG, together with CXCL10 and CXCL11, may activate CXCR3 by binding to it. CXCL9 serves as a cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. It has been observed that tumour endothelial cells secrete high levels of CXCL9 in all, and CXCL10 in most melanoma metastases. Experiment data represent novel mechanisms by which tumour cells in melanoma metastases might use the chemokine-expressing endothelium to leave the tumour and eventually to form additional metastases at distinct sites. Experiment results also improved that CXCL9/MIG plays an important role in CD4+ T lymphocyte recruitment and development of CAV, MOMA-2+ macrophages are the predominant recipient-derived source of CXCL9/MIG, and recipient CD4 lymphocytes are necessary for sustained CXCL9/MIG production and CAV development in this model. Neutralization of the chemokine CXCL9/MIG may have therapeutic potential for the treatment of chronic rejection after heart transplantation.

## Basic Information

### Description

Recombinant Mouse CXCL9/MIG Protein is produced by *Pichia* expression system. The target protein is expressed with sequence (Thr 22-Thr 126) of mouse CXCL9/MIG (Accession #NP\_032625.2) fused with a His tag at the C-terminus..

### Bio-Activity

### Storage

Store at -20°C. Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt.


After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.

Avoid repeated freeze/thaw cycles.

\* For your safety and health, please wear a lab coat and disposable gloves when handling.

## Validation Data

---



Recombinant Mouse CXCL9/MIG  
Protein was determined by SDS-  
PAGE under reducing conditions with  
Coomassie Blue.